Monocyte chemoattractant protein-1–glycosaminoglycan interaction (MCP-1–GAG interaction)

The Monocyte chemoattractant protein-1–glycosaminoglycan (MCP-1–GAG) interaction is a fundamental mechanism in the inflammatory response, where the chemokine MCP-1 (also known as CCL2) binds to glycosaminoglycans like heparan sulfate on endothelial surfaces and the extracellular matrix (Proudfoot et al., 2003, PNAS). This binding is essential for the oligomerization of MCP-1 and the establishment of a stable haptotactic gradient, which guides monocytes and other leukocytes to the site of injury or infection (Handel et al., 2005, Annu. Rev. Biochem.). Without GAG binding, MCP-1 remains in a monomeric state and is easily washed away by blood flow, failing to trigger effective leukocyte extravasation (Lau et al., 2004, J. Biol. Chem.). In chronic diseases such as atherosclerosis, rheumatoid arthritis, and diabetic nephropathy, this interaction is pathologically upregulated, leading to excessive tissue infiltration of inflammatory cells (Bedke et al., 2010, Nephrol. Dial. Transplant.). Therapeutic targeting of this interaction involves the use of decoy chemokines or small molecules that competitively inhibit the MCP-1–GAG interface, thereby disrupting the recruitment signal without necessarily blocking the CCR2 receptor directly (Ali et al., 2005, J. Biol. Chem.). Such strategies, including the development of engineered mutants like PA401, aim to provide a more localized anti-inflammatory effect compared to systemic receptor antagonists (Piccinini et al., 2016, Expert Opin. Ther. Targets).

Other names

CCL2–GAG interactionMCP-1–heparan sulfate interactionChemokine–glycosaminoglycan interactionCCL2–HS interaction

Competitive inhibition of the chemokine-glycosaminoglycan binding site to prevent the formation of a haptotactic gradient and disrupt chemokine oligomerization, thereby inhibiting leukocyte extravasation.